BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

ABSTRACT Objectives B‐cell maturation antigen (BCMA)‐targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real‐world impact within EMMY, a French longitudinal cohort. Methods Patients initiating a fourth or later line of therapy (L4+) between 2017 and 2023 across 73 centers were included. Temporal trends in treatment use were described. Outcomes, including progression‐free survival (PFS) and time to next treatment (TTNT), were compared between patients treated with BCMA‐targeted therapies and other regimens. Analyses were performed at the patient level and at the treatment‐line level. Safety data were not collected. Results Among 1362 patients treated in L4+, 294 (21.6%) received a BCMA‐targeted regimen. Use increased from 2.4% in 2019 to 52.0% in 2023, driven by bispecific antibodies. Outcomes improved over time, with median TTNT rising from 8.0 months in 2017 to 12.1 months in 2022, and median PFS from 7.2 to 9.3 months. In L4, BCMA‐targeted therapies were associated with longer TTNT (21.7 vs. 9.3 months; p = 0.007) and PFS (13.4 vs. 7.9 months; p = 0.015). Similar trends were observed in later lines. Conclusions BCMA‐targeted therapies were rapidly integrated into real‐world practice and were associated with improved outcomes in late‐line RRMM.

Authors

Institutions

Publication Details

Journal
European Journal Of Haematology
Published
2026-09-29
DOI
https://doi.org/10.1111/ejh.70334
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

Ariane Boumendil, Hélène Demarquette, Claire Jouzier, Lionel Karlin et al.
European Journal Of Haematology
Multiple Myeloma Research and Treatments
article

BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort

Ariane Boumendil, Hélène Demarquette, Claire Jouzier, Lionel Karlin, Olivier Thierry Allangba, Titouan Cazaubiel, Cécile Sonntag, Julie Gay, Cyrille Touzeau, Arthur Bobin, Karim Belhadj, Margaret Macro, Stéphane Darre, Laure Vincent, Thomas Chalopin, Bruno Royer, Benoît Bareau, Aurore Perrot, Cyrille Hulin, Laurent Frenzel, Jean‐Valère Malfuson, Olivier Decaux, Jean Eudes Fontan, EMMY and the IFM group, Mohamad Mohty
article en

Abstract

ABSTRACT Objectives B‐cell maturation antigen (BCMA)‐targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real‐world impact within EMMY, a French longitudinal cohort. Methods Patients initiating a fourth or later line of therapy (L4+) between 2017 and 2023 across 73 centers were included. Temporal trends in treatment use were described. Outcomes, including progression‐free survival (PFS) and time to next treatment (TTNT), were compared between patients treated with BCMA‐targeted therapies and other regimens. Analyses were performed at the patient level and at the treatment‐line level. Safety data were not collected. Results Among 1362 patients treated in L4+, 294 (21.6%) received a BCMA‐targeted regimen. Use increased from 2.4% in 2019 to 52.0% in 2023, driven by bispecific antibodies. Outcomes improved over time, with median TTNT rising from 8.0 months in 2017 to 12.1 months in 2022, and median PFS from 7.2 to 9.3 months. In L4, BCMA‐targeted therapies were associated with longer TTNT (21.7 vs. 9.3 months; p = 0.007) and PFS (13.4 vs. 7.9 months; p = 0.015). Similar trends were observed in later lines. Conclusions BCMA‐targeted therapies were rapidly integrated into real‐world practice and were associated with improved outcomes in late‐line RRMM.

European Journal Of Haematology
Centre Hospitalier Universitaire de Grenoble (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), Université de Poitiers (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire de Tours (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Hospices Civils de Lyon (FR), Hôpital Saint-Antoine (FR), Centre Hospitalier de Saint-Brieuc (FR), Laboratoire National de Référence (MA), Hôpital Lyon Sud (FR), Centre Hospitalier Universitaire de Caen Normandie (FR), CIC Rennes (FR), Hôpital Cardiologique du Haut-Lévêque (FR), Intergroupe Francophone du Myélome (FR), Centre Hospitalier de la Côte Basque (FR), Hôpital Privé Jean Mermo (FR), Centre Hospitalier d'Arras (FR), Hôpital d'instruction des Armées Percy (FR), Hôpital Saint-Louis (FR), Lymphoma Study Association (FR), Centre Hospitalier Universitaire de Rennes (FR), Hôpital d'Hautepierre (FR)
Openalex Percentile: Top 11%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.